Hahn Confirmation Hearing: Pharma May Be Left Parsing Non-Rx Questions For Policy Clues
Executive Summary
US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.
You may also be interested in...
Drug Development Questions Dominate Hahn's Confirmation, Despite Talk About E-Cigs
A plurality of the questions from the Senate HELP Committee at Stephen Hahn's confirmation hearing to head the US FDA focused on drug development issues, despite the time lawmakers spent discussing the agency's regulation of e-cigarettes.
Hahn Confirmation Hearing: Solid Performance Light On Substance
US FDA commissioner nominee Stephen Hahn does not offer much detail on his policy positions; Senate confirmation could be completed by the end of the year.
US Sen. Patty Murray To Grill FDA Commissioner Nominee Stephen Hahn On Prioritizing Science Over Ideology
During a planned confirmation hearing on oncologist Stephen Hahn to become commissioner of the US Food and Drug Administration, a key Senate committee ranking member, Democrat Patty Murray of Washington State, said she will be vetting Hahn on his commitment to promoting science at the agency.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
